{
  "id": 20671529,
  "title": "Intuitive Surgical evp Mark Brosius sells $60,367 in shares",
  "url": "https://urgent.news/2026/11/18/intuitive-surgical-evp-mark-brosius-sells-60-367-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T23:01:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/intuitive-surgical-evp-mark-brosius-sells-60367-in-shares-93CH-5037318"
  },
  "original_language": "en",
  "account": "Intuitive Surgical's Executive Vice President and Chief Manufacturing and Supply Chain Officer, Mark Brosius, sold a total of $60,367 worth of company shares. The transactions occurred over three days, with share prices ranging between $430.63 and $444.38. Intuitive Surgical, valued at $149 billion, is currently trading below its InvestingPro Fair Value, indicating potential for investors. On November 16, 2026, Brosius disposed of 46 shares at $444.38 per share. The next day, he sold another 46 shares at $437.33, and on November 18, 2026, he sold the final 46 shares at $430.63. These sales were part of a pre-planned trading strategy pursuant to an SEC Rule 10b5-1 plan, which will expire on February 14, 2027. Brosius now directly owns 319 shares of Intuitive Surgical common stock. Following the sales, the company reported third-quarter revenue of $3.05 billion, exceeding estimates from Oppenheimer ($2.92 billion) and consensus expectations ($2.91 billion). However, GAAP earnings per share were $1.49, falling short of Oppenheimer's $2.38 estimate and the consensus $2.39 estimate, due to a $450 million litigation settlement. Despite this, Intuitive Surgical maintained a Buy rating with a $550 price target from Stifel, highlighting strong procedure growth. Truist Securities also reiterated a Buy rating with a $510 price target, citing a 40% increase in net da Vinci placements. RBC Capital lowered its price target to $550 from $575, expressing concerns over U.S. volume deceleration, but maintained an Outperform rating. BMO Capital reiterated an Outperform rating with a $518 price target, emphasizing the positive outlook for outpatient robotics. Oppenheimer also maintained an Outperform rating with a $500 price target after the earnings report. These developments indicate mixed analyst sentiment but generally positive outlooks for Intuitive Surgical.",
  "summary": null,
  "key_points": [
    "Mark Brosius, EVP and Chief Manufacturing Officer, sold $60,367 worth of Intuitive Surgical shares.",
    "Sales occurred over three days with share prices between $430.63 and $444.38.",
    "Following sales, Intuitive Surgical reported Q3 revenue of $3.05 billion, surpassing estimates."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}